Sintilimab Plus Ipilimumab N01 and Chemotherapy Versus Sintilimab Plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma With PD-L1 CPS <5
Key facts
- Who runs it
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Where
- China3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 525 people, planned
- Starts
- 20 Nov 2026
- Expected to end
- 31 Dec 2030
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- sintilimab+IBI310+chemotherapy
- sintilimab+chemotherapy
- Record updated
- 17 November 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Aged 18-75 years
- Histologically confirmed advanced gastric or gastroesophageal junction adenocarcinoma without prior systemic therapy
- HER2-negative status
- At least one measurable or evaluable lesion per RECIST v1.1
- PD-L1 CPS <5, assessed using the PD-L1 IHC 22C3 assay on pretreatment tumor tissue and confirmed by a local or central laboratory
- ECOG PS 0-1
- Life expectancy ≥3 months
Who cannot take part
- Unresolved Grade >1 toxicity from prior anticancer therapy, with protocol-defined exceptions
- Known DPD deficiency or prior Grade ≥3 fluoropyrimidine-related mucosal toxicity
- Intestinal obstruction within 28 days before treatment, unless surgically resolved or completely recovered
- Active tumor bleeding
- Grade ≥3 hypersensitivity to monoclonal antibodies or chemotherapy components
- History of seizures, CNS metastases, spinal cord compression, or meningeal metastases
- Clinically significant cardiovascular or cerebrovascular disease
- History of severe toxicity requiring permanent discontinuation of immune checkpoint inhibitors or study-related treatment
- History of noninfectious enteritis requiring corticosteroids within 1 year before treatment
- Uncontrolled bleeding, bleeding tendency, severe non-healing wounds, ulcers, fractures, or high-risk varices or portal hypertension
- Pregnant or breastfeeding women, or those planning pregnancy within 6 months after treatment
- Severe gastrointestinal obstruction or difficulty swallowing tablets
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a multicenter, randomized, controlled Phase III clinical study designed to evaluate the efficacy and safety of sintilimab plus ipilimumab N01 and chemotherapy compared with sintilimab plus chemotherapy as first-line treatment for patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with a programmed death-ligand 1 (PD-L1) combined positive score (CPS) of less than 5.
Read full original descriptionShow less
Eligible patients will be randomly assigned to receive either sintilimab plus ipilimumab N01 and chemotherapy or sintilimab plus chemotherapy. The study aims to determine whether the addition of ipilimumab N01 to sintilimab plus chemotherapy can improve clinical outcomes in this patient population while evaluating the safety of the combination regimen.
The 2 groups in the trial
- Experimental ArmTreatment being tested
Sintilimab Plus Ipilimumab N01 and Chemotherapy
Treatment: sintilimab+IBI310+chemotherapy
- Active ComparatorExisting treatment, for comparison
Sintilimab Plus Chemotherapy
Treatment: sintilimab+chemotherapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Sintilimab Plus Ipilimumab N01 and Chemotherapy Versus Sintilimab Plus Chemotherapy as First-Line Treatment for Patients With PD-L1 CPS <5 Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: A Randomized, Controlled, Multicenter, Phase III Clinical Study
- Criteria questions
- Built from NCT07942285, who can take part
- Record updated
- 17 November 2026